• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

RBC Transfusions Improve Quality of Life for Some Patients with Cancer

June 6, 2019

Hematology and oncology outpatients often receive RBC transfusions to maintain critical hemoglobin (Hb) thresholds, but the impact of these transfusions on quality of life is not well understood. In order to investigate the effectiveness of these transfusions, 208 outpatients aged at least 50 years with a hematologic or oncologic diagnosis were enrolled in the prospective Red Cells in Outpatients Transfusion Outcomes (RETRO) study. All 208 study participants were given three tests the day of transfusion and again 5-10 days post transfusion: the 6-minute walk test distance, fatigue- and dyspnea-related quality of life tests. Overall, patients improved a median of 20 meters in unadjusted walk test distance (IQR, -6 to 47 m; p<0.001), and a median of 3 points in their fatigue score (IQR, -2 to 9; p<0.001). No clinically significant changes were observed in dyspnea scores. Although some patients did not improve, almost 80% of patients who had not received recent cancer treatment showed improvement in either walk test performance (>20 m) or fatigue score (>3 points) after transfusion. Based on multivariable analyses of changes in the walk test, greater gains were predicted in stable patients without recent cancer treatment and a post-transfusion Hb level >8 g/dL. Quality of life considerations along with clinical thresholds may all impact the decision to transfuse hematology/oncology patients.

Reference:

St. Lezin E, Karafin MS, Bruhn R, Chowdhury D, et al for the NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS)-III Program. Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study. Transfusion 2019

Filed Under

  • CME
  • News
  • RBC Transfusion

Recommended

  • Scientists Design a Bioreactor to Produce Platelets In Vitro

  • Whole Blood Derived Platelet vs. Apheresis Platelets

  • VIDEO: Older Red Blood Cells are Not Associated with Adverse Outcomes in Transfused Cardiac Surgery Patients

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • RBCs with Reduced Deformability are Removed from Circulation

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley